Home' Australian Pharmacist : Australian Pharmacist April 2015 Contents Australian Pharmacist April 2015 I ©Pharmaceutical Society of Australia Ltd.
Guardian Pharmacy has scored
a trifecta by winning the 2014
Roy Morgan Research Customer
Satisfaction Award for Pharmacy
for the third year running.
Gary Dunne, Sigma Chief Operating
Officer said: 'Sigma and our Guardian
members have put significant effort into
ensuring we consistently deliver the
health programs, products and services
our customers want, and that we take
the time to care and interact with
customers and help provide healthcare
solutions. This has again resulted in
Guardian scoring consistently high in
customer satisfaction ratings across
Michele Levine, CEO, Roy Morgan
Research, said: 'Since their inception
four years ago, the Roy Morgan
Research Customer Satisfaction Awards
have earned a reputation as the most
accurate and reliable measure of
customer satisfaction in the country.
By aggregating 12 months' worth of
responses to our Consumer Single
Source and Business Single Source
surveys, Roy Morgan is able to identify
and celebrate those businesses -- large
and small -- that have outperformed
their competitors in Customer
The Guardian brand is part of Sigma
APHS Packaging has been rebranded
as DoseAid to better reflect what the
company plans to become.
APHS Packaging National Manager Seth
Grantley said: 'The APHS Packaging
name and its branding were outdated.
They didn't reflect who we are, what we
do, and what we plan to become.
'We use cutting-edge technology
to provide our customers and their
patients with a vital health management
service -- we're growing to be much
more than just a packaging business.'
Symbion retained the name APHS
Packaging when it acquired the business
in February, 2012. The new name is
effective immediately, with DoseAid
branding being rolled out over the
As part of the rebrand Mr Grantley said
the company would be updating and
expanding its range of medication
compliance products and services,
which would facilitate improved health
outcomes for the community through its
Mr Grantley said that by outsourcing
Dose Administration Aids (DAAs)
pharmacies could ensure accuracy and
convenience for their customers while
saving labour costs.
'DoseAid saves pharmacies valuable
time and money, and gives them peace
of mind knowing they're providing a
high level of care to their customers,'
ACCC satis ed
The Australian Competition and
Consumer Commission (ACCC) will
not oppose GlaxoSmithKline's (GSK)
and Novartis' transactions involving
over-the-counter consumer products,
human vaccines and oncology products.
ACCC Commissioner Dr Jill Walker said
the ACCC was satisfied, taking into
account undertakings by the companies,
that each of the three proposed
acquisitions was unlikely to substantially
As a result of undertakings to the ACCC,
GSK will divest Meningococcal vaccine
products in Australia and Novartis will
divest its smoking cessation products
including the Nicotinell brand. As a result
of the undertaking to the European
Commission, Novartis is divesting, on a
global basis, two in-development drugs
to treat advanced melanoma.
'The ACCC worked closely with the
European Commission, the US Federal
Trade Commission and the New Zealand
Commerce Commission in assessing
these transactions. Where undertakings
provided to the European Commission
have resolved competition concerns
in Australia, the ACCC has taken a
pragmatic approach and not sought
standalone undertakings in Australia,'
Dr Walker said.
'The global commitments to divest the
melanoma products in development are
important for consumers and protect
competition in the future. It reflects the
approach of the ACCC to consider not
only products now on the market, but
also the competitive impact of products
that are in development.'
GSK and Novartis overlap in the
supply of Meningococcal vaccines in
Australia and over the counter products
including smoking cessation and pain
management products. In relation
to oncology products, Novartis has a
number of drugs used to treat advanced
melanoma in development which
are likely to compete with existing
Links Archive Australian Pharmacist March 2015 Australian Pharmacist May 2015 Navigation Previous Page Next Page